Japan's Kyowa Hakko Kirin Co. Ltd. (KHK) has reacquired global rights to tivozanib in non-oncology settings from licensee Aveo Pharmaceuticals Inc., which will now focus its efforts on development and commercialization of the multi-VEGF inhibitor in the oncology field.
The move will generate further cash for the US oncology specialist, in the form of a $25m upfront payment within...